Nebivolol and S(-) Amlodipine Tablet

NEBROOT-AM

Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets

Division: DIABGLYM

Composition

Each tablet contains:

Nebivolol IP — 5 mg

S(-) Amlodipine IP — 5 mg

Excipients — q.s.

Colour: Approved colour used

Dosage form: Oral tablet

Product Description

NEBROOT-AM is a scientifically balanced antihypertensive combination of Nebivolol 5 mg and S(-) Amlodipine 5 mg, formulated for the effective management of hypertension and long-term cardiovascular protection. This combination provides dual blood pressure control by combining the highly selective beta-1 blocking and nitric oxide-mediated vasodilatory effects of Nebivolol with the sustained vasodilatory action of S(-) Amlodipine, resulting in superior antihypertensive efficacy and improved cardiovascular outcomes.

Nebivolol is a third-generation beta-1 selective blocker with additional nitric oxide-mediated vasodilatory properties that helps reduce heart rate, myocardial oxygen demand, and vascular resistance while improving endothelial function. S(-) Amlodipine is the pharmacologically active isomer of amlodipine that provides effective arterial vasodilation with improved efficacy and a lower incidence of peripheral edema compared with conventional racemic amlodipine.

NEBROOT-AM is particularly beneficial in patients with hypertension associated with tachycardia, coronary artery disease, diabetes, metabolic syndrome, elderly hypertension, and patients requiring combination antihypertensive therapy with heart rate control.

Technical Knowledge of Nebivolol and S(-) Amlodipine

Nebivolol selectively blocks beta-1 adrenergic receptors in the heart and stimulates endothelial nitric oxide release, producing vasodilation, reduced heart rate, decreased myocardial contractility, improved endothelial function, and enhanced vascular compliance.

S(-) Amlodipine selectively inhibits L-type calcium channels in vascular smooth muscle, producing sustained arterial vasodilation, reducing peripheral vascular resistance, improving vascular compliance, and maintaining stable blood pressure control throughout the dosing interval.

The combination of Nebivolol and S(-) Amlodipine provides complementary antihypertensive mechanisms with additional cardiovascular and endothelial protective benefits.

Mechanism of Action

Nebivolol selectively blocks beta-1 receptors, reduces heart rate and myocardial contractility, stimulates nitric oxide-mediated vasodilation, improves endothelial function, decreases peripheral vascular resistance, and reduces myocardial oxygen demand.

S(-) Amlodipine blocks L-type calcium channels, relaxes vascular smooth muscle, reduces arterial resistance, improves vascular compliance, enhances coronary blood flow, and provides sustained antihypertensive action.

Key Benefits

Effective reduction of systolic and diastolic blood pressure

Dual antihypertensive mechanism

Provides sustained 24-hour blood pressure control

Reduces heart rate and myocardial workload

Supports cardiovascular protection

Improves endothelial function

Enhances vascular compliance

May reduce the incidence of peripheral edema

Suitable for long-term hypertension management under medical supervision

Clinical Applications

NEBROOT-AM is commonly prescribed for essential hypertension, hypertension with tachycardia, hypertension with coronary artery disease, hypertension with diabetes mellitus, metabolic syndrome, elderly hypertension, and long-term cardiovascular risk reduction.

Facts About Nebivolol and S(-) Amlodipine

Nebivolol is a modern beta-blocker with nitric oxide-mediated vasodilatory activity and excellent metabolic and endothelial profiles. S(-) Amlodipine is the active isomer responsible for the therapeutic antihypertensive effect of amlodipine and is associated with effective blood pressure control and improved tolerability. The combination is particularly useful in hypertensive patients requiring both blood pressure reduction and heart rate control.

Key Facts

Beta-blocker and calcium channel blocker combination therapy

Nebivolol 5 mg for heart rate control and endothelial support

S(-) Amlodipine 5 mg for sustained arterial vasodilation

Provides comprehensive blood pressure and heart rate control

Effective in hypertension with coronary artery disease and diabetes

Evidence-based cardiovascular combination therapy

Quality-assured pharmaceutical formulation

PCD Pharma Franchise Opportunity

NEBROOT-AM is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, coronary artery disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.

Why Choose NEBROOT-AM for PCD Pharma Franchise?

High prescription potential

Strong physician and cardiologist acceptance

Attractive monopoly franchise opportunity

Competitive pricing

Promotional support available

Visual aids and marketing inputs

Consistent product quality

Excellent repeat business potential

Third Party Manufacturing

Chemsroot Pharmaceutical offers Third Party Manufacturing of Nebivolol 5 mg and S(-) Amlodipine 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.

Our Third Party Manufacturing Services Include

Private label manufacturing

Contract manufacturing

Custom brand manufacturing

Loan license manufacturing

DCGI-compliant production

GMP-certified manufacturing

Batch manufacturing documentation

Product registration support

Customized packaging and artwork

Monopoly franchise packaging

Bulk manufacturing capability

Manufacturing Features

Pharmaceutical-grade raw materials

IP/BP/USP quality standards

In-process quality control

Finished product testing

Stability-oriented formulation

Moisture-controlled tablet manufacturing

Blister and Alu-Alu packaging options

NEBROOT-AM from DIABGLYM combines effective blood pressure control, heart rate management, comprehensive cardiovascular protection, evidence-based combination therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nebivolol and S(-) Amlodipine formulation.